[P02BB01, trichlorfon, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Metrifonate.]
[S02DA03, antipyrine, The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Trimebutine.]
[J01GA01, streptomycin, Trimebutine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA27, fingolimod, Fingolimod may increase the bradycardic activities of Trimebutine.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01CG01, sulbactam, Trimebutine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Trimebutine.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Sulindac is combined with Trimebutine.]
[N05AL01, sulpiride, Trimebutine may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Azapropazone is combined with Trimebutine.]
[N06DA01, tacrine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Tacrine.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Trimebutine.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Trimebutine.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Tetrabenazine.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A04AD10, dronabinol, The risk or severity of Tachycardia and drowsiness can be increased when Trimebutine is combined with Dronabinol.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L04AX02, thalidomide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Trimebutine.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01AC01, thiotepa, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AC02, thioridazine, Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01BB04, aprindine, Aprindine may increase the arrhythmogenic activities of Trimebutine.]
[B02AB01, aprotinin, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Aprotinin.]
[G04BE06, moxisylyte, Trimebutine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Trimebutine is combined with Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[S01AA12, tobramycin, Trimebutine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Tolazamide.]
[M02AX02, tolazoline, The risk or severity of hypotension can be increased when Tolazoline is combined with Trimebutine.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Trimebutine.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02AX02, tramadol, The risk or severity of adverse effects can be increased when Trimebutine is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Trimebutine.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Mepenzolate is combined with Trimebutine.]
[S01EB04, demecarium, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Demecarium.]
[A16AX12, trientine, Triethylenetetramine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Trimebutine.]
[S01ED04, metipranolol, Trimebutine may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Trimebutine.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Trimethaphan is combined with Trimebutine.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Trimebutine.]
[N06AA06, trimipramine, Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Trimebutine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Tropicamide is combined with Trimebutine.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Trimebutine.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R03DX07, roflumilast, Roflumilast may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01FX04, ipilimumab, Ipilimumab may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[S01AA05, tyrothricin, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Tyrothricin.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Vandetanib.]
[R02AA14, oxyquinoline, Trimebutine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The metabolism of Trimebutine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Trimebutine can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Trimebutine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Trimebutine.]
[S01AA28, vancomycin, Trimebutine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[B01AF01, rivaroxaban, Rivaroxaban may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Trimebutine.]
[C08DA01, verapamil, Verapamil may increase the arrhythmogenic activities of Trimebutine.]
[N06AX09, viloxazine, The metabolism of Trimebutine can be decreased when combined with Viloxazine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[B01AA03, warfarin, Trimebutine may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Trimebutine can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Pipemidic acid.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J05AE02, indinavir, The metabolism of Trimebutine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trimebutine.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[B06AC02, icatibant, Icatibant may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Trimebutine.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Trimebutine.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Deferiprone may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Trimebutine.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Trimebutine.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Trimebutine.]
[J01DH04, doripenem, Doripenem may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Trimebutine.]
[J02AC03, voriconazole, The metabolism of Trimebutine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Trimebutine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[B03XA04, peginesatide, Peginesatide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Trimebutine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Trimebutine is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Trimebutine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Trimebutine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Trimebutine can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Trimebutine.]
[A02AA05, magnesium silicate, The risk or severity of hypotension can be increased when Magnesium silicate is combined with Trimebutine.]
[C01CA18, octopamine, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Octopamine.]
[L01EX05, regorafenib, Regorafenib may increase the bradycardic activities of Trimebutine.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Trimebutine.]
[D02BA02, octinoxate, Trimebutine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Trimebutine can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Trimebutine.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06DA02, donepezil, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L04AA29, tofacitinib, Tofacitinib may increase the bradycardic activities of Trimebutine.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Thonzylamine.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Trimebutine.]
[V09IX04, fluorodeoxyglucose F18, Trimebutine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Trimebutine.]
[V08CA11, gadofosveset, Gadofosveset trisodium may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A16AX08, teduglutide, Teduglutide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Bedaquiline.]
[C04AX11, bencyclane, Trimebutine may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, Glycerol phenylbutyrate may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Benorilate.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Gemifloxacin.]
[A12CC09, magnesium orotate, The risk or severity of hypotension can be increased when Magnesium orotate is combined with Trimebutine.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Moxifloxacin.]
[A06AX06, tegaserod, The therapeutic efficacy of Tegaserod can be decreased when used in combination with Trimebutine.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin detemir.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Trimebutine.]
[L03AA12, ancestim, Trimebutine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Trimebutine.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A12CC05, magnesium aspartate, The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Trimebutine.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Trimebutine.]
[L01EC02, dabrafenib, The serum concentration of Trimebutine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hyperkalemia can be increased when Benzydamine is combined with Trimebutine.]
[L01EE01, trametinib, Trametinib may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[V09AX05, florbetapir F-18, Trimebutine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C08EA02, bepridil, Bepridil may increase the arrhythmogenic activities of Trimebutine.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Lixisenatide.]
[C02KX04, macitentan, Macitentan may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J05AP05, simeprevir, The metabolism of Trimebutine can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Sofosbuvir may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Droxidopa may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C07AB04, acebutolol, Acebutolol may increase the arrhythmogenic activities of Trimebutine.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A16AA07, metreleptin, The metabolism of Trimebutine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, Apremilast may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L02BG02, formestane, Formestane may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A16AA06, betaine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Betaine.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Trimebutine.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C02CC01, bethanidine, The risk or severity of Tachycardia can be increased when Bethanidine is combined with Trimebutine.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Albiglutide.]
[L01ED02, ceritinib, Trimebutine may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Trimebutine.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Trimebutine.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Trimebutine is combined with Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05CM19, suvorexant, Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[V04CX03, methacholine, Trimebutine may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Trimebutine.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Dulaglutide.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Trimebutine is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Trimebutine.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Trimebutine.]
[S03AA06, gentamicin, Trimebutine may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AF03, edoxaban, Edoxaban may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N06AX11, mirtazapine, Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Difemerine.]
[C01EB17, ivabradine, Trimebutine may increase the bradycardic activities of Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Trimebutine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A06AD03, magnesium peroxide, The risk or severity of hypotension can be increased when Magnesium peroxide is combined with Trimebutine.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of hyperkalemia can be increased when Aceclofenac is combined with Trimebutine.]
[M01AB11, acemetacin, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin degludec.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[V03AB37, idarucizumab, Trimebutine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J02AC05, isavuconazole, The metabolism of Trimebutine can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Trimebutine.]
[L01XG03, ixazomib, Trimebutine may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Acetohexamide.]
[G04CA01, alfuzosin, The risk or severity of hypotension can be increased when Alfuzosin is combined with Trimebutine.]
[M04AB05, lesinurad, Trimebutine may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Alminoprofen.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01XX52, venetoclax, The metabolism of Trimebutine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A02AD05, aluminum magnesium silicate, Trimebutine may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Trimebutine.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C07AA19, bupranolol, Bupranolol may increase the arrhythmogenic activities of Trimebutine.]
[N07BC01, buprenorphine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Trimebutine.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Artemether.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Trimebutine is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Trimebutine.]
[S01GX07, azelastine, Azelastine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Azithromycin.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Trimebutine.]
[L01EF02, ribociclib, The metabolism of Trimebutine can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hyperkalemia can be increased when Balsalazide is combined with Trimebutine.]
[R03CC12, bambuterol, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Bambuterol.]
[A06AH05, naldemedine, Trimebutine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C09AA07, benazepril, The risk or severity of hyperkalemia can be increased when Benazepril is combined with Trimebutine.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Benfluorex.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[P01CA02, benznidazole, Trimebutine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[G04BA03, calcium chloride, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium chloride.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Trimebutine can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium gluconate.]
[N07XX13, valbenazine, Trimebutine may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L01EX10, midostaurin, The metabolism of Trimebutine can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Delafloxacin.]
[D01AC10, bifonazole, The therapeutic efficacy of Bifonazole can be increased when used in combination with Trimebutine.]
[P03AC02, bioallethrin, Trimebutine may increase the arrhythmogenic activities of Bioallethrin.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Trimebutine.]
[C07AB07, bisoprolol, The therapeutic efficacy of Trimebutine can be increased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of Tachycardia can be increased when Bitolterol is combined with Trimebutine.]
[J05AG03, efavirenz, The serum concentration of Trimebutine can be decreased when it is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C07AA17, bopindolol, The risk or severity of bradycardia can be increased when Trimebutine is combined with Bopindolol.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Bornaprine.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Budesonide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Bumadizone.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01AA02, acetyldigoxins, Trimebutine may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Semaglutide.]
[N01BX04, capsaicin, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Acrivastine.]
[C09AA01, captopril, The risk or severity of hyperkalemia can be increased when Captopril is combined with Trimebutine.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Trimebutine.]
[L02BB05, apalutamide, The metabolism of Trimebutine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Trimebutine can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Trimebutine.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Camylofin.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C07AG02, carvedilol, Carvedilol may increase the arrhythmogenic activities of Trimebutine.]
[N03AX24, cannabidiol, The risk or severity of Tachycardia and drowsiness can be increased when Trimebutine is combined with Cannabidiol.]
[L04AA37, baricitinib, Trimebutine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Encorafenib.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01GB14, plazomicin, Trimebutine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Celiprolol may increase the arrhythmogenic activities of Trimebutine.]
[L01XX62, ivosidenib, The metabolism of Trimebutine can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Trimebutine can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Carbutamide.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[D08AE05, chloroxylenol, Trimebutine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Trimebutine.]
[M01AC05, lornoxicam, The risk or severity of hyperkalemia can be increased when Lornoxicam is combined with Trimebutine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Inotersen.]
[M03BA02, carisoprodol, Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Trimebutine is combined with Revefenacin.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Amifampridine.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Trimebutine.]
[C01BG07, cifenline, Trimebutine may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of hyperkalemia can be increased when Cilazapril is combined with Trimebutine.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Trimebutine.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01ED05, carteolol, Trimebutine may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Triclabendazole.]
[N06AX27, esketamine, Esketamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J01FA09, clarithromycin, The metabolism of Trimebutine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Trimebutine.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Trimebutine.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[V03AE07, calcium acetate, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Candesartan.]
[A12CC06, magnesium lactate, The risk or severity of hypotension can be increased when Magnesium lactate is combined with Trimebutine.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C03BX03, cicletanine, Trimebutine may increase the arrhythmogenic activities of Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Trimebutine can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Trimebutine.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin pork.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Trimebutine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Trimebutine.]
[N03AX25, cenobamate, The serum concentration of Trimebutine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[M09AX08, golodirsen, Trimebutine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Trimebutine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Dezocine.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Trimebutine.]
[J05AE05, amprenavir, The metabolism of Trimebutine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R02AA03, dichlorobenzyl alcohol, Trimebutine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Trimebutine may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M01AH02, rofecoxib, The risk or severity of hyperkalemia can be increased when Rofecoxib is combined with Trimebutine.]
[C08CA16, clevidipine, Clevidipine may increase the arrhythmogenic activities of Trimebutine.]
[C01BD07, dronedarone, Dronedarone may increase the arrhythmogenic activities of Trimebutine.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Trimebutine.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Trimebutine.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Dopexamine.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Trimebutine.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Droxicam.]
[V08CA05, mangafodipir, Mangafodipir may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[M02AA27, dexketoprofen, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Fostemsavir.]
[N05CD14, remimazolam, Remimazolam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N07XX04, sodium oxybate, Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L04AC19, satralizumab, The serum concentration of Trimebutine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of urinary retention, reduced gastrointestinal motility, and constipation can be increased when Trimebutine is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Chloroquine.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Ethenzamide.]
[N02BA03, choline salicylate, Trimebutine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, Trimebutine may increase the arrhythmogenic activities of Vinpocetine.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M01AB08, etodolac, The risk or severity of hyperkalemia can be increased when Etodolac is combined with Trimebutine.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Etofenamate is combined with Trimebutine.]
[B06AC06, berotralstat, The metabolism of Trimebutine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Trimebutine can be decreased when combined with Lonafarnib.]
[M09AA01, hydroquinine, Trimebutine may increase the arrhythmogenic activities of Hydroquinine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Trimebutine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Trimebutine can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Fenbufen is combined with Trimebutine.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Fenozolone.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Trimebutine.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N02BG07, flupirtine, Flupirtine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Trimebutine.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Trimebutine.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A02BA01, cimetidine, The serum concentration of Trimebutine can be increased when it is combined with Cimetidine.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Trimebutine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Trimebutine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Trimebutine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Trimebutine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, Citalopram may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Trimebutine is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Ioflupane I-123 may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Trimebutine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Trimebutine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M01AG01, mefenamic acid, The risk or severity of hyperkalemia can be increased when Mefenamic acid is combined with Trimebutine.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Gliquidone.]
[R03CC13, clenbuterol, The risk or severity of Tachycardia can be increased when Clenbuterol is combined with Trimebutine.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium glubionate anhydrous.]
[N06AX25, St. John's wort extract, The metabolism of Trimebutine can be increased when combined with St. John's Wort.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Trimebutine.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Pacritinib.]
[N06AA04, clomipramine, Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01EA04, clonidine, Clonidine may increase the atrioventricular blocking (AV block) activities of Trimebutine.]
[C01EB24, mavacamten, The serum concentration of Trimebutine can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Tirzepatide.]
[J02AC06, oteseconazole, The therapeutic efficacy of Oteseconazole can be increased when used in combination with Trimebutine.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AH02, clozapine, Clozapine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Sotagliflozin.]
[J01GB12, arbekacin, Trimebutine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[H01AC08, somatrogon, The metabolism of Trimebutine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Cocaine.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M04AC01, colchicine, Colchicine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Hexocyclium is combined with Trimebutine.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Trimebutine.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Homatropine.]
[J01XB01, colistin, Trimebutine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C01BA13, hydroquinidine, Trimebutine may increase the arrhythmogenic activities of Hydroquinidine.]
[A02AD04, hydrotalcite, The risk or severity of hypotension can be increased when Hydrotalcite is combined with Trimebutine.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A04AA03, tropisetron, Trimebutine may increase the arrhythmogenic activities of Tropisetron.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Trimebutine can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Indobufen.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C05BB03, invert sugar, Trimebutine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[V08AB05, iopromide, Trimebutine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Trimebutine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Trimebutine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Trimebutine.]
[H01AX01, pegvisomant, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Pegvisomant.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be increased when it is combined with Trimebutine.]
[A03AX10, isometheptene, The risk or severity of Tachycardia can be increased when Isometheptene is combined with Trimebutine.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M01AH04, parecoxib, The risk or severity of hyperkalemia can be increased when Parecoxib is combined with Trimebutine.]
[J02AC02, itraconazole, The metabolism of Trimebutine can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Emedastine.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Kebuzone is combined with Trimebutine.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Trimebutine can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Trimebutine may increase the arrhythmogenic activities of Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Trimebutine.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Trimebutine.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N07BC04, lofexidine, Lofexidine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Lonazolac.]
[R06AX13, loratadine, Trimebutine may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Trimebutine.]
[A02AD02, magaldrate, The risk or severity of hypotension can be increased when Magaldrate is combined with Trimebutine.]
[A06AD01, magnesium carbonate, The risk or severity of hypotension can be increased when Magnesium carbonate is combined with Trimebutine.]
[C08CA11, manidipine, Trimebutine may increase the arrhythmogenic activities of Manidipine.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Mefenorex.]
[C07AA14, mepindolol, The risk or severity of bradycardia can be increased when Trimebutine is combined with Mepindolol.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Trimebutine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C01EB10, adenosine, Adenosine may increase the arrhythmogenic activities of Trimebutine.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Trimebutine.]
[C04AX01, cyclandelate, Cyclandelate may increase the arrhythmogenic activities of Trimebutine.]
[R03CB02, methoxyphenamine, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Trimebutine may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Miglitol.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Trimebutine.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01XA18, cyclosporine, The metabolism of Trimebutine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Trimebutine.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Trimebutine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Moxonidine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Trimebutine.]
[M01AH05, etoricoxib, The risk or severity of hyperkalemia can be increased when Etoricoxib is combined with Trimebutine.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Trimebutine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Trimebutine.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A04AD11, nabilone, The risk or severity of Tachycardia and drowsiness can be increased when Trimebutine is combined with Nabilone.]
[M01AX01, nabumetone, The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Trimebutine.]
[N07BB05, nalmefene, Nalmefene may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Trimebutine.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C07AB12, nebivolol, Nebivolol may increase the arrhythmogenic activities of Trimebutine.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Trimebutine can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01DX16, nicorandil, Trimebutine may increase the arrhythmogenic activities of Nicorandil.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01CA05, norfenefrine, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Trimebutine is combined with Normethadone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N06AB10, escitalopram, Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Trimebutine.]
[A07EC03, olsalazine, The risk or severity of hyperkalemia can be increased when Olsalazine is combined with Trimebutine.]
[N06AA01, desipramine, Desipramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01AA07, deslanoside, Deslanoside may increase the arrhythmogenic activities of Trimebutine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[V04CH02, indigo carmine, Trimebutine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Trimebutine.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Trimebutine.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S03BA01, dexamethasone, The metabolism of Trimebutine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Dexetimide is combined with Trimebutine.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Trimebutine.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Trimebutine.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Trimebutine is combined with Dextromoramide.]
[N06AB05, paroxetine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[B01AC04, clopidogrel, The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Trimebutine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Trimebutine is combined with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Trimebutine may increase the vasodilatory activities of Pentaerythritol tetranitrate.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R05DA08, pholcodine, Trimebutine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Trimebutine.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Trimebutine.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Trimebutine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A03AX04, pinaverium, Trimebutine may increase the arrhythmogenic activities of Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Pioglitazone.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Trimebutine is combined with Pipenzolate.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Erlotinib.]
[R03CC07, pirbuterol, The risk or severity of Tachycardia can be increased when Pirbuterol is combined with Trimebutine.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Trimebutine.]
[D07XC04, diflucortolone, Trimebutine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Poldine.]
[N02BA11, diflunisal, The risk or severity of hyperkalemia can be increased when Diflunisal is combined with Trimebutine.]
[C01AA04, digitoxin, Digitoxin may increase the arrhythmogenic activities of Trimebutine.]
[C01AA05, digoxin, Digoxin may increase the arrhythmogenic activities of Trimebutine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Trimebutine is combined with Hydromorphone.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Trimebutine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Trimebutine.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Trimebutine.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Trimebutine.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[V03AB09, dimercaprol, Dimercaprol may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Dimetindene is combined with Trimebutine.]
[R03CC08, procaterol, The risk or severity of Tachycardia can be increased when Procaterol is combined with Trimebutine.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Proglumetacin.]
[R06AA02, diphenhydramine, Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Trimebutine is combined with Diphenoxylate.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C09AA06, quinapril, The risk or severity of hyperkalemia can be increased when Quinapril is combined with Trimebutine.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A03FA02, cisapride, Cisapride may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C09AA05, ramipril, The risk or severity of hyperkalemia can be increased when Ramipril is combined with Trimebutine.]
[S01XA23, sirolimus, Trimebutine may increase the immunosuppressive activities of Sirolimus.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R03CC14, reproterol, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Reproterol.]
[S01AX06, resorcinol, Trimebutine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Trimebutine.]
[N07AA03, distigmine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Distigmine.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Trimebutine.]
[S02AA12, rifamycin SV, The metabolism of Trimebutine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Trimebutine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Trimebutine.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Trimebutine.]
[A04AD12, aprepitant, The metabolism of Trimebutine can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Trimebutine.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[S01BC05, ketorolac, The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Trimebutine.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Salsalate is combined with Trimebutine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Trimebutine.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Trimebutine.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N06AA16, dothiepin, Dosulepin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AA12, doxepin, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Trimebutine.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AB06, sertraline, Sertraline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N01AB08, sevoflurane, The risk or severity of hypotension can be increased when Sevoflurane is combined with Trimebutine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A08AA10, sibutramine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Trimebutine.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Trimebutine.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Spirapril is combined with Trimebutine.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[V04CX07, edrophonium, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Edrophonium.]
[C07AB13, talinolol, Trimebutine may increase the arrhythmogenic activities of Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Temafloxacin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of hyperkalemia can be increased when Tenoxicam is combined with Trimebutine.]
[G04CA03, terazosin, The risk or severity of hypotension can be increased when Terazosin is combined with Trimebutine.]
[G04BD05, terodiline, Trimebutine may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Trimebutine may increase the arrhythmogenic activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The risk or severity of Tachycardia can be increased when Tetryzoline is combined with Trimebutine.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[G04BD01, emepronium, Emepronium may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C09AA02, enalapril, The risk or severity of hyperkalemia can be increased when Enalapril is combined with Trimebutine.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M01AG02, tolfenamic acid, Trimebutine may increase the bradycardic activities of Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Trimebutine.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Trimebutine is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Tramazoline.]
[C09AA10, trandolapril, The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Trimebutine.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Trimebutine.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Trimebutine.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Tulobuterol.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Trimebutine.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01FB02, ephedrine, The risk or severity of Tachycardia can be increased when Ephedrine is combined with Trimebutine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01CX07, xamoterol, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Xamoterol.]
[S01GA03, xylometazoline, Xylometazoline may increase the arrhythmogenic activities of Trimebutine.]
[C08CA12, mepirodipine, Trimebutine may increase the arrhythmogenic activities of Barnidipine.]
[S01EA01, epinephrine, The risk or severity of Tachycardia can be increased when Epinephrine is combined with Trimebutine.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Zofenopril.]
[N05CF02, zolpidem, Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Zomepirac is combined with Trimebutine.]
[N03AX15, zonisamide, Zonisamide may increase the arrhythmogenic activities of Trimebutine.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin glulisine.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01BG01, moricizine, Moricizine may increase the arrhythmogenic activities of Trimebutine.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02CA02, ergotamine, The metabolism of Trimebutine can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01DA13, erythrityl tetranitrate, Trimebutine may increase the vasodilatory activities of Erythrityl tetranitrate.]
[L03AX05, pidotimod, Trimebutine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Trimebutine.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Gepefrine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Trimebutine.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Trimebutine.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Trimebutine.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M01AC06, meloxicam, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Trimebutine.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of Tachycardia can be increased when Etilefrine is combined with Trimebutine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01BA05, ajmaline, Ajmaline may increase the arrhythmogenic activities of Trimebutine.]
[L04AD02, tacrolimus, Trimebutine may increase the immunosuppressive activities of Tacrolimus.]
[A02BA04, nizatidine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Trimebutine.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Trimebutine can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AB08, fluvoxamine, Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01BB03, tocainide, Tocainide may increase the arrhythmogenic activities of Trimebutine.]
[C01BC08, encainide, Encainide may increase the arrhythmogenic activities of Trimebutine.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Leuprolide.]
[M01CB01, gold sodium thiomalate, Trimebutine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Trimebutine may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Trimebutine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C08CA02, felodipine, Felodipine may increase the arrhythmogenic activities of Trimebutine.]
[C08EA01, fendiline, Fendiline may increase the arrhythmogenic activities of Trimebutine.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Trimebutine.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Trimebutine.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Trimebutine is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Trimebutine.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Flavoxate is combined with Trimebutine.]
[C01BC04, flecainide, Flecainide may increase the arrhythmogenic activities of Trimebutine.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Floctafenine is combined with Trimebutine.]
[J02AC01, fluconazole, The metabolism of Trimebutine can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N07CA03, flunarizine, Flunarizine may increase the arrhythmogenic activities of Trimebutine.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[V03AZ01, ethanol, Ethanol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Trimebutine.]
[N05AF01, flupenthixol, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01BC04, flurbiprofen, The risk or severity of hyperkalemia can be increased when Flurbiprofen is combined with Trimebutine.]
[N05AG01, fluspirilene, Fluspirilene may increase the arrhythmogenic activities of Trimebutine.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01BC03, tegafur, Trimebutine may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, The risk or severity of Tachycardia can be increased when Adrafinil is combined with Trimebutine.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J05AE10, darunavir, The serum concentration of Trimebutine can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Trimebutine.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C08DA02, gallopamil, Trimebutine may increase the arrhythmogenic activities of Gallopamil.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C10AB04, gemfibrozil, Gemfibrozil may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Trimebutine.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Trimebutine.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Liraglutide.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium levulinate.]
[N03AD03, methsuximide, Methsuximide may increase the arrhythmogenic activities of Trimebutine.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Trimebutine is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Trimebutine.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Glipizide.]
[H04AA01, glucagon, Trimebutine may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Trimebutine.]
[C05AE01, nitroglycerin, Trimebutine may increase the vasodilatory activities of Nitroglycerin.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Trimebutine.]
[C02CA04, doxazosin, The risk or severity of hypotension can be increased when Doxazosin is combined with Trimebutine.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Trimebutine.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Trimebutine.]
[M01CB04, aurothioglucose, Trimebutine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C09AA09, fosinopril, The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Trimebutine.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Haloperidol.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Trimebutine.]
[N05AH04, quetiapine, Quetiapine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06BX13, idebenone, Idebenone may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin aspart.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C09CA01, losartan, Losartan may increase the arrhythmogenic activities of Trimebutine.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Trimebutine.]
[B05CB03, magnesium citrate, The risk or severity of hypotension can be increased when Magnesium citrate is combined with Trimebutine.]
[A12CC03, magnesium gluconate, The risk or severity of hypotension can be increased when Magnesium gluconate is combined with Trimebutine.]
[G03DC01, allylestrenol, Allylestrenol may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Trimebutine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Trimebutine.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R03CC05, hexoprenaline, The risk or severity of Tachycardia can be increased when Hexoprenaline is combined with Trimebutine.]
[C08CA10, nilvadipine, Nilvadipine may increase the arrhythmogenic activities of Trimebutine.]
[M02AA26, nimesulide, Nimesulide may increase the arrhythmogenic activities of Trimebutine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Oxatomide.]
[C09AA04, perindopril, The risk or severity of hyperkalemia can be increased when Perindopril is combined with Trimebutine.]
[C02DB02, hydralazine, Hydralazine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Trimebutine.]
[R05DA03, hydrocodone, The risk or severity of adverse effects can be increased when Trimebutine is combined with Hydrocodone.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Trimebutine.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Trimebutine.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of hypotension can be increased when Propiverine is combined with Trimebutine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Trimebutine.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[B05AA07, hetastarch, Trimebutine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Hydroxyzine.]
[C02AC06, rilmenidine, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Trimebutine.]
[B05XA08, sodium acetate, Trimebutine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Trimebutine.]
[L01AA06, ifosfamide, Ifosfamide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Trimebutine is combined with Sufentanil.]
[N06AA02, imipramine, Imipramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Terlipressin.]
[R01AD07, tixocortol, Trimebutine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Trimebutine.]
[S01BC01, indomethacin, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Trimebutine.]
[C02CA02, indoramin, The risk or severity of hypotension can be increased when Indoramin is combined with Trimebutine.]
[A11HA07, inositol, Trimebutine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Trimebutine is combined with Piperidolate.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Sitagliptin.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Trimebutine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Vildagliptin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Anagrelide.]
[C07AA01, alprenolol, Alprenolol may increase the arrhythmogenic activities of Trimebutine.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Trimebutine may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R03CC06, isoetharine, The risk or severity of Tachycardia can be increased when Isoetharine is combined with Trimebutine.]
[C09AA16, imidapril, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Imidapril.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01EB07, isoflurophate, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J04AC01, isoniazid, The metabolism of Trimebutine can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Trimebutine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Isoprenaline.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Exenatide.]
[C01DA14, isosorbide mononitrate, Trimebutine may increase the vasodilatory activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, Trimebutine may increase the vasodilatory activities of Isosorbide dinitrate.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of Tachycardia can be increased when Isoxsuprine is combined with Trimebutine.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01AA24, kanamycin, Trimebutine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[B01AC22, prasugrel, Prasugrel may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Trimebutine can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Trimebutine can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M02AA10, ketoprofen, The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Trimebutine.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Mizolastine.]
[C01CA22, arbutamine, The risk or severity of Tachycardia can be increased when Arbutamine is combined with Trimebutine.]
[N04BC09, rotigotine, Rotigotine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Tiaprofenic acid is combined with Trimebutine.]
[C07AG01, labetalol, The risk or severity of bradycardia can be increased when Trimebutine is combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Trimebutine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Trimebutine.]
[N07AA30, ambenonium, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Trimebutine.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Trimebutine.]
[S02DA01, lidocaine, Lidocaine may increase the arrhythmogenic activities of Trimebutine.]
[C08EX01, lidoflazine, Trimebutine may increase the arrhythmogenic activities of Lidoflazine.]
[S01AA21, amikacin, Trimebutine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A07DA03, loperamide, Loperamide may increase the arrhythmogenic activities of Trimebutine.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium pangamate.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C10AA02, lovastatin, The metabolism of Trimebutine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[B05XA11, magnesium chloride, The risk or severity of hypotension can be increased when Magnesium chloride is combined with Trimebutine.]
[G04BX01, magnesium hydroxide, The risk or severity of hypotension can be increased when Magnesium hydroxide is combined with Trimebutine.]
[A12CC10, magnesium oxide, The risk or severity of hypotension can be increased when Magnesium oxide is combined with Trimebutine.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the arrhythmogenic activities of Trimebutine.]
[L01BA05, pralatrexate, Pralatrexate may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Trimebutine can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Trimebutine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M02AA18, meclofenamic acid, The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Trimebutine.]
[C01AA08, medigoxin, Trimebutine may increase the arrhythmogenic activities of Metildigoxin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Trimebutine.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Trimebutine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Nadroparin is combined with Trimebutine.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Trimebutine.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Trimebutine.]
[N05CH01, melatonin, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Melatonin.]
[N06DX01, memantine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of Tachycardia can be increased when Mephentermine is combined with Trimebutine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Trimebutine is combined with Meptazinol.]
[G04BX16, tiopronin, Tiopronin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05AX13, paliperidone, Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01CA09, metaraminol, The risk or severity of Tachycardia can be increased when Metaraminol is combined with Trimebutine.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Metformin.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[H01CB03, lanreotide, Lanreotide may increase the bradycardic activities of Trimebutine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Trimebutine is combined with Methadone.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Trimebutine.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[H03BB02, methimazole, The metabolism of Trimebutine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Trimebutine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N02BG08, ziconotide, Ziconotide may increase the arrhythmogenic activities of Trimebutine.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01CA10, methoxamine, The risk or severity of Tachycardia can be increased when Methoxamine is combined with Trimebutine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Trimebutine.]
[C02AB01, methyldopa, Methyldopa may increase the bradycardic activities of Trimebutine.]
[V04CG05, methylene blue, Methylene blue may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N03AF03, rufinamide, Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[G03EK01, methyltestosterone, Methyltestosterone may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Trimebutine.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Trimebutine.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Trimebutine.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Trimebutine.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Trimebutine.]
[S02AA13, miconazole, The metabolism of Trimebutine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hyperkalemia can be increased when Aminophenazone is combined with Trimebutine.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Parnaparin.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01CA17, midodrine, Midodrine may increase the bradycardic activities of Trimebutine.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Trimebutine.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Trimebutine.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Trimebutine.]
[L01XX23, mitotane, The metabolism of Trimebutine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Trimebutine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Trimebutine.]
[N06AA09, amitriptyline, Amitriptyline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Certolizumab pegol may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Ammonium chloride is combined with Trimebutine.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Pazopanib.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Trimebutine.]
[G04CA04, silodosin, The risk or severity of hypotension can be increased when Silodosin is combined with Trimebutine.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Trimebutine is combined with Ipratropium.]
[N06AA17, amoxapine, Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N03AB05, fosphenytoin, The metabolism of Trimebutine can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Nadolol may increase the arrhythmogenic activities of Trimebutine.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01CF06, nafcillin, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Nafcillin.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Trimebutine can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Trimebutine is combined with Naltrexone.]
[S01GA01, naphazoline, The risk or severity of Tachycardia can be increased when Naphazoline is combined with Trimebutine.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of hyperkalemia can be increased when Naproxen is combined with Trimebutine.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Troglitazone.]
[N06AX21, duloxetine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S03AA01, neomycin, Trimebutine may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Trimebutine is combined with Remifentanil.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Repaglinide.]
[C01CX08, levosimendan, Levosimendan may increase the arrhythmogenic activities of Trimebutine.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[S01EB06, neostigmine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J02AA01, amphotericin B, Trimebutine may decrease the nephrotoxic activities of Amphotericin B.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[L03AX16, plerixafor, Plerixafor may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[S01AA23, netilmicin, Trimebutine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Trimebutine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Trimebutine.]
[C04AE02, nicergoline, The risk or severity of hypotension can be increased when Nicergoline is combined with Trimebutine.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Trimebutine.]
[C08CA05, nifedipine, Nifedipine may increase the arrhythmogenic activities of Trimebutine.]
[M02AA17, niflumic acid, The risk or severity of hyperkalemia can be increased when Niflumic acid is combined with Trimebutine.]
[V03AB22, amyl nitrite, Trimebutine may increase the vasodilatory activities of Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Trimebutine.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Trimebutine.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C08CA08, nitrendipine, Nitrendipine may increase the arrhythmogenic activities of Trimebutine.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Trimebutine.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C02DD01, nitroprusside, Trimebutine may increase the hypotensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01CA03, norepinephrine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Trimebutine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Trimebutine.]
[N06AA10, nortriptyline, Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[G02CA02, nylidrin, Nylidrin may increase the arrhythmogenic activities of Trimebutine.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Trimebutine is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Trimebutine.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Ofloxacin.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Trimebutine is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Trimebutine.]
[G04CA02, tamsulosin, The risk or severity of hypotension can be increased when Tamsulosin is combined with Trimebutine.]
[C01AC01, ouabain, The serum concentration of Ouabain can be increased when it is combined with Trimebutine.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Oxprenolol may increase the arrhythmogenic activities of Trimebutine.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Trimebutine is combined with Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Trimebutine.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Trimebutine is combined with Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Oxyphenbutazone is combined with Trimebutine.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Trimebutine.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimebutine.]
[N05AH05, asenapine, Asenapine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Danaparoid is combined with Trimebutine.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Trimebutine is combined with Tapentadol.]
[M03AC01, pancuronium, Pancuronium may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J04AB30, capreomycin, Trimebutine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Papaverine.]
[N05CC05, paraldehyde, Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Trimebutine.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Fesoterodine is combined with Trimebutine.]
[C07AA23, penbutolol, The risk or severity of bradycardia can be increased when Trimebutine is combined with Penbutolol.]
[N05AG03, penfluridol, Trimebutine may increase the arrhythmogenic activities of Penfluridol.]
[J01CE09, penicillin G procaine, Trimebutine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Trimebutine can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Trimebutine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C08EX02, perhexiline, Perhexiline may increase the arrhythmogenic activities of Trimebutine.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Phenformin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Trimebutine.]
[N03AA02, phenobarbital, The metabolism of Trimebutine can be increased when combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Trimebutine.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Trimebutine.]
[A08AA01, phentermine, The risk or severity of Tachycardia can be increased when Phentermine is combined with Trimebutine.]
[V03AB36, phentolamine, The risk or severity of hypotension can be increased when Phentolamine is combined with Trimebutine.]
[M02AA01, phenylbutazone, The risk or severity of hyperkalemia can be increased when Phenylbutazone is combined with Trimebutine.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be decreased when Trimebutine is combined with Phenylephrine.]
[R01BA01, phenylpropanolamine, The risk or severity of Tachycardia can be increased when Phenylpropanolamine is combined with Trimebutine.]
[N03AB02, phenytoin, The metabolism of Trimebutine can be increased when combined with Phenytoin.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Levofloxacin.]
[V03AB19, physostigmine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Physostigmine.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C08CX01, mibefradil, Mibefradil may increase the arrhythmogenic activities of Trimebutine.]
[N05AG02, pimozide, Pimozide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C07AA03, pindolol, The risk or severity of bradycardia can be increased when Trimebutine is combined with Pindolol.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Trimebutine can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N06BX03, piracetam, Trimebutine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Trimebutine.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Trimebutine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Trimebutine is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hyperkalemia can be increased when Piroxicam is combined with Trimebutine.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Grepafloxacin.]
[N02CX01, pizotyline, Pizotifen may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J05AG02, delavirdine, The metabolism of Trimebutine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Trimebutine.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Rosiglitazone.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Trimebutine.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Trimebutine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Saxagliptin.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Trimebutine is combined with Potassium chloride.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Trimebutine.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin lispro.]
[C07AB01, practolol, Practolol may increase the arrhythmogenic activities of Trimebutine.]
[C01BA08, prajmaline, Trimebutine may increase the arrhythmogenic activities of Prajmaline.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Trimebutine.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Antazoline.]
[C01DX02, prenylamine, Prenylamine may increase the arrhythmogenic activities of Trimebutine.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[P01BA03, primaquine, The metabolism of Trimebutine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Trimebutine can be increased when combined with Primidone.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Probucol.]
[C01BA02, procainamide, Procainamide may increase the arrhythmogenic activities of Trimebutine.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Trimebutine.]
[N05AA03, promazine, Promazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD02, promethazine, Promethazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01BC03, propafenone, Propafenone may increase the arrhythmogenic activities of Trimebutine.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Trimebutine.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CM06, propiomazine, Propiomazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Romidepsin.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Trimebutine is combined with Dextropropoxyphene.]
[C07AA05, propranolol, Propranolol may increase the arrhythmogenic activities of Trimebutine.]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be increased when it is combined with Trimebutine.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[B01AC09, epoprostenol, Epoprostenol may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R01BA02, pseudoephedrine, The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Trimebutine.]
[N05AX12, aripiprazole, Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N07XX07, dalfampridine, Dalfampridine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Trimebutine is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Isopropamide is combined with Trimebutine.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Methscopolamine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Trimebutine.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[C01BA01, quinidine, Quinidine may increase the arrhythmogenic activities of Trimebutine.]
[P01BC01, quinine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Trimebutine.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Trimebutine can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of Tachycardia can be increased when Trimebutine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of Tachycardia can be increased when Ritodrine is combined with Trimebutine.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Salicylamide is combined with Trimebutine.]
[A07EC01, sulfasalazine, The risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Trimebutine.]
[S01BC08, salicylic acid, The risk or severity of hyperkalemia can be increased when Salicylic acid is combined with Trimebutine.]
[S01FA02, scopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Trimebutine.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[J01GB08, sisomicin, Trimebutine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Trimebutine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Trimebutine.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Trimebutine.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
